Spyre Therapeutics, Inc. — Director's Dealing 2021

Nov 16, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aeglea BioTherapeutics, Inc. (AGLE)
CIK: 0001636282
Period of Report: 2021-11-12

Reporting Person: Smith Hunter C (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-12	Director Stock Option (right to buy)	$7.04	A	60000	Acquired	2031-11-11	Common Stock (60000)	Direct

Footnotes

F1: The stock option vests and becomes exercisable in 36 equal monthly installments beginning on December 12, 2021 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.